- Home
- KINS vs GLSI Comparison
KINS vs GLSI Comparison
Compare KINS & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KINS | GLSI |
|---|---|---|
| Founded | 1886 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.5M | 254.7M |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KINS | GLSI |
|---|---|---|
| Price | $20.10 | $17.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $57.00 |
| AVG Volume (30 Days) | 57.8K | ★ 123.9K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | ★ 1.20% | N/A |
| EPS Growth | ★ 94.59 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $214,867,301.00 | N/A |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $15.85 | N/A |
| P/E Ratio | $30.33 | ★ N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.83 | $7.78 |
| 52 Week High | $20.90 | $34.10 |
Technical Indicators
Market Signals| Indicator | KINS | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 53.98 |
| Support Level | $18.52 | $14.44 |
| Resistance Level | $20.52 | $18.00 |
| Average True Range (ATR) | 0.47 | 1.34 |
| MACD | 0.13 | 0.30 |
| Stochastic Oscillator | 90.55 | 64.89 |
Price Performance
Historical ComparisonAbout KINS Kingstone Companies Inc.
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.